Skip to main content
Top
Published in: Dermatology and Therapy 2/2014

Open Access 01-12-2014 | Original Research

A New, Objective, Quantitative Scale for Measuring Local Skin Responses Following Topical Actinic Keratosis Therapy with Ingenol Mebutate

Authors: Robert Rosen, Ellen Marmur, Lawrence Anderson, Peter Welburn, Janelle Katsamas

Published in: Dermatology and Therapy | Issue 2/2014

Login to get access

Abstract

Introduction

Local skin responses (LSRs) are the most common adverse effects of topical actinic keratosis (AK) therapy. There is currently no method available that allows objective characterization of LSRs. Here, the authors describe a new scale developed to quantitatively and objectively assess the six most common LSRs resulting from topical AK therapy with ingenol mebutate.

Methods

The LSR grading scale was developed using a 0–4 numerical rating, with clinical descriptors and representative photographic images for each rating. Good inter-observer grading concordance was demonstrated in peer review during development of the tool. Data on the use of the scale are described from four phase III double-blind studies of ingenol mebutate (n = 1,005).

Results

LSRs peaked on days 4 (face/scalp) or 8 (trunk/extremities), with mean maximum composite LSR scores of 9.1 and 6.8, respectively, and a rapid return toward baseline by day 15 in most cases. Mean composite LSR score at day 57 was generally lower than at baseline.

Conclusion

The LSR grading scale is an objective tool allowing practicing dermatologists to characterize and compare LSRs to existing and, potentially, future AK therapies.
Appendix
Available only for authorised users
Literature
1.
go back to reference Salasche SJ. Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol. 2000;42:4–7.PubMedCrossRef Salasche SJ. Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol. 2000;42:4–7.PubMedCrossRef
2.
go back to reference Misiewicz J, Sendagorta E, Golebiowska A, Lorenc B, Czarnetzki BM, Jablonska S. Topical treatment of multiple actinic keratoses of the face with arotinoid methyl sulfone (Ro 14-9706) cream versus tretinoin cream: a double-blind, comparative study. J Am Acad Dermatol. 1991;24:448–51.PubMedCrossRef Misiewicz J, Sendagorta E, Golebiowska A, Lorenc B, Czarnetzki BM, Jablonska S. Topical treatment of multiple actinic keratoses of the face with arotinoid methyl sulfone (Ro 14-9706) cream versus tretinoin cream: a double-blind, comparative study. J Am Acad Dermatol. 1991;24:448–51.PubMedCrossRef
3.
go back to reference Grimaitre M, Etienne A, Fathi M, Piletta PA, Saurat JH. Topical colchicine therapy for actinic keratoses. Dermatology. 2000;200:346–8.PubMedCrossRef Grimaitre M, Etienne A, Fathi M, Piletta PA, Saurat JH. Topical colchicine therapy for actinic keratoses. Dermatology. 2000;200:346–8.PubMedCrossRef
4.
go back to reference Jorizzo JL. Current and novel treatment options for actinic keratosis. J Cutan Med Surg. 2005;8(Suppl 3):13–21. Jorizzo JL. Current and novel treatment options for actinic keratosis. J Cutan Med Surg. 2005;8(Suppl 3):13–21.
5.
go back to reference Lebwohl M, Dinehart S, Whiting D, et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol. 2004;50:714–21.PubMedCrossRef Lebwohl M, Dinehart S, Whiting D, et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol. 2004;50:714–21.PubMedCrossRef
8.
go back to reference Food and Drug Administration (FDA). Memorandum of meeting minutes. Pre-phase 2 guidance meeting for IND 70,114, PEP005 topical gel for topical treatment of actinic keratoses. USA: FDA Communication; 2006. Food and Drug Administration (FDA). Memorandum of meeting minutes. Pre-phase 2 guidance meeting for IND 70,114, PEP005 topical gel for topical treatment of actinic keratoses. USA: FDA Communication; 2006.
9.
go back to reference Freeman M, Oakley A, Siller G, et al. Study to determine the optimal tolerated regimen of ingenol mebutate (PEP005) gel for actinic keratosis of the face or face and scalp. Poster P2010 presented at the American Academy of Dermatology (AAD) Summer Academy Meeting, Chicago, IL, USA, July 30 to August 3, 2008. Freeman M, Oakley A, Siller G, et al. Study to determine the optimal tolerated regimen of ingenol mebutate (PEP005) gel for actinic keratosis of the face or face and scalp. Poster P2010 presented at the American Academy of Dermatology (AAD) Summer Academy Meeting, Chicago, IL, USA, July 30 to August 3, 2008.
10.
go back to reference Spencer J. Multicenter, randomized, double-blind, vehicle-controlled, dose-ranging study to evaluate the efficacy and safety of PEP005 (ingenol mebutate) gel 0.005%, 0.01%, and 0.015% when used to treat actinic keratoses on the head. J Am Acad Dermatol. 2010;62(3 Suppl 1):AB105 (Poster P2913). Spencer J. Multicenter, randomized, double-blind, vehicle-controlled, dose-ranging study to evaluate the efficacy and safety of PEP005 (ingenol mebutate) gel 0.005%, 0.01%, and 0.015% when used to treat actinic keratoses on the head. J Am Acad Dermatol. 2010;62(3 Suppl 1):AB105 (Poster P2913).
11.
go back to reference Anderson L, Schmieder GJ, Werschler WP, et al. Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis. J Am Acad Dermatol. 2009;60:934–43.PubMedCrossRef Anderson L, Schmieder GJ, Werschler WP, et al. Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis. J Am Acad Dermatol. 2009;60:934–43.PubMedCrossRef
12.
go back to reference Lebwohl M, Swanson N, Anderson LL, Melgaard A, Xu Z, Berman B. Ingenol mebutate gel for actinic keratosis. N Engl J Med. 2012;366:1010–9.PubMedCrossRef Lebwohl M, Swanson N, Anderson LL, Melgaard A, Xu Z, Berman B. Ingenol mebutate gel for actinic keratosis. N Engl J Med. 2012;366:1010–9.PubMedCrossRef
13.
go back to reference Steffen E, Bertsch HP, Haenssle HA, Zibert JR, Schön M, Schön MP. Pharmacodynamics of ingenol mebutate 0.05% gel for the treatment of actinic keratosis assessed by histology. J Am Acad Dermatol. 2013;68(4 Suppl 1):AB163 (Abstract P6969). Steffen E, Bertsch HP, Haenssle HA, Zibert JR, Schön M, Schön MP. Pharmacodynamics of ingenol mebutate 0.05% gel for the treatment of actinic keratosis assessed by histology. J Am Acad Dermatol. 2013;68(4 Suppl 1):AB163 (Abstract P6969).
14.
go back to reference Ulrich M, Völker-Call M, Lange-Asschenfeldt S, et al. Assessment of the in vivo effects of ingenol mebutate 0.05% gel for the treatment of actinic field cancerization by reflectance confocal microscopy. Poster 334 presented at the 10th Meeting of the International Confocal Working Group (ICWG), Prague, Czech Republic, September 28, 2012. Ulrich M, Völker-Call M, Lange-Asschenfeldt S, et al. Assessment of the in vivo effects of ingenol mebutate 0.05% gel for the treatment of actinic field cancerization by reflectance confocal microscopy. Poster 334 presented at the 10th Meeting of the International Confocal Working Group (ICWG), Prague, Czech Republic, September 28, 2012.
15.
go back to reference Berman B, Swanson N, Goldenberg G, et al. Field treatment with ingenol mebutate gel, 0.015%, 3 weeks after cryosurgery of actinic keratosis is safe and effective. Poster at the Winter Clinical Dermatology Conference of the American Academy of Dermatology, Koloa, HI, USA, January 18–23, 2013. Berman B, Swanson N, Goldenberg G, et al. Field treatment with ingenol mebutate gel, 0.015%, 3 weeks after cryosurgery of actinic keratosis is safe and effective. Poster at the Winter Clinical Dermatology Conference of the American Academy of Dermatology, Koloa, HI, USA, January 18–23, 2013.
16.
go back to reference Ramsay JR, Suhrbier A, Aylward JH, et al. The sap from Euphorbia peplus is effective against human nonmelanoma skin cancers. Br J Dermatol. 2011;164:633–6.PubMed Ramsay JR, Suhrbier A, Aylward JH, et al. The sap from Euphorbia peplus is effective against human nonmelanoma skin cancers. Br J Dermatol. 2011;164:633–6.PubMed
17.
go back to reference Spencer J. Multicenter, randomized, double-blind, vehicle-controlled, dose-ranging study to evaluate the efficacy and safety of PEP005 (ingenol mebutate) gel 0.005%, 0.01%, and 0.015% when used to treat actinic keratoses on the head. Poster P2913 at the 68th Annual Meeting of the American Academy of Dermatology (AAD), Miami, FL, USA, March 5–9, 2010. Spencer J. Multicenter, randomized, double-blind, vehicle-controlled, dose-ranging study to evaluate the efficacy and safety of PEP005 (ingenol mebutate) gel 0.005%, 0.01%, and 0.015% when used to treat actinic keratoses on the head. Poster P2913 at the 68th Annual Meeting of the American Academy of Dermatology (AAD), Miami, FL, USA, March 5–9, 2010.
18.
go back to reference Sinnya S, McEniery E, Soyer HP, Tan J-M, Oesterdal ML. Safety of LEO 43204 in a first in man trial of actinic keratosis on the forearms. J Am Acad Dermatol. 2014;70(Suppl):AB139 (Abstract P7942). Sinnya S, McEniery E, Soyer HP, Tan J-M, Oesterdal ML. Safety of LEO 43204 in a first in man trial of actinic keratosis on the forearms. J Am Acad Dermatol. 2014;70(Suppl):AB139 (Abstract P7942).
19.
go back to reference Freeman M, Rosen R, Zibert JR, Knudsen KM, Spelman L. Ingenol mebutate gel topically applied under occlusion to superficial basal cell carcinoma is efficacious compared with marginal effect in seborrheic keratosis. J Am Acad Dermatol. 2014;70(Suppl):AB136 (Poster 7934). Freeman M, Rosen R, Zibert JR, Knudsen KM, Spelman L. Ingenol mebutate gel topically applied under occlusion to superficial basal cell carcinoma is efficacious compared with marginal effect in seborrheic keratosis. J Am Acad Dermatol. 2014;70(Suppl):AB136 (Poster 7934).
20.
go back to reference Siller G, Rosen R, Freeman M, Welburn P, Katsamas J, Ogbourne SM. PEP005 (ingenol mebutate) gel for the topical treatment of superficial basal cell carcinoma: results of a randomized phase IIa trial. Australas J Dermatol. 2010;51:99–105.PubMedCrossRef Siller G, Rosen R, Freeman M, Welburn P, Katsamas J, Ogbourne SM. PEP005 (ingenol mebutate) gel for the topical treatment of superficial basal cell carcinoma: results of a randomized phase IIa trial. Australas J Dermatol. 2010;51:99–105.PubMedCrossRef
Metadata
Title
A New, Objective, Quantitative Scale for Measuring Local Skin Responses Following Topical Actinic Keratosis Therapy with Ingenol Mebutate
Authors
Robert Rosen
Ellen Marmur
Lawrence Anderson
Peter Welburn
Janelle Katsamas
Publication date
01-12-2014
Publisher
Springer Healthcare
Published in
Dermatology and Therapy / Issue 2/2014
Print ISSN: 2193-8210
Electronic ISSN: 2190-9172
DOI
https://doi.org/10.1007/s13555-014-0059-9

Other articles of this Issue 2/2014

Dermatology and Therapy 2/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.